Related Experiment Video
Updated: Dec 26, 2025
10:32
Hippocampal Insulin Microinjection and In vivo Microdialysis During Spatial Memory Testing
Published on: January 11, 2013
16.9K
Insulin pens: the modern delivery devices
1Excel Care Hospitals, Maya-Ville, Borthakur Mill Road, Ulubari, Guwahati, Assamn, 78100, India.
The Journal of the Association of Physicians of India
|August 9, 2011
Summary
Modern insulin pens offer a convenient alternative to traditional syringes for diabetes management. These devices improve ease of use and lifestyle integration, potentially enhancing glycemic control and patient quality of life.
Area of Science:
- Endocrinology
- Diabetes Management
Background:
- Strict glycemic control is crucial for reducing diabetes complications and mortality.
- Insulin therapy is the cornerstone of diabetes treatment.
- Conventional insulin delivery via syringes presents significant barriers, including inconvenience and dosing errors.
Purpose of the Study:
- To evaluate the advantages of modern insulin pen devices over conventional syringe delivery methods.
- To assess the impact of insulin pens on patient adherence, convenience, and quality of life.
Main Methods:
- Comparative analysis of insulin delivery systems.
- Review of user-friendliness and injection comfort associated with insulin pens.
Main Results:
- Insulin pens offer enhanced user-friendliness and injection comfort compared to syringes.
- The ease of use and flexibility of insulin pens facilitate integration into patients' lifestyles.
- Potential for improved diabetes control with reduced patient effort.
Conclusions:
- Modern insulin pens represent a significant advancement in insulin delivery.
- Insulin pens can improve patient experience, adherence, and quality of life in diabetes management.
- Both reusable and prefilled insulin pen options are available to suit patient needs.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
557
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
557
01:16Insulin: Dosing Regimen and Adverse Effects
581
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
581
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.1K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
505
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
505
01:24Glucagon-like Receptor Agonists
757
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
757
01:05Insulin Secretory Vesicles
6.3K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
6.3K